title: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging.
authors.affiliation: Houston Methodist Research Institute, Houston, TX, USA. pzfregonara@gmail.com.
authors.forename: Paolo
authors.initials: P
authors.lastname: Zanotti-Fregonara
authors.affiliation: Service de Médecine Nucléaire - CHU de Bordeaux; UMR-CNRS 5287; LabEx TRAIL, Université de Bordeaux, Bordeaux, France.
authors.forename: Clément
authors.initials: C
authors.lastname: Morgat
authors.affiliation: CNRS/IN2P3, Centre d'Etudes Nucléaires de Bordeaux Gradignan (CENBG), Université de Bordeaux, Bordeaux, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Champion
authors.affiliation: Service de Médecine Nucléaire - CHU de Bordeaux; UMR-CNRS 5287; LabEx TRAIL, Université de Bordeaux, Bordeaux, France.
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
mesh_terms: D006801:Humans; D018358:Neuroendocrine Tumors; D015282:Octreotide; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D017481:Receptors, Somatostatin
chemical_list: D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D017481:Receptors, Somatostatin; D015282:Octreotide